drugset / Trial / NCT00345774

Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

NCT00345774 ↗

Phase 2 Completed 72 enrolled Epix Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being conducted to see if PRX-08066 can lower pulmonary artery pressures in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.

Timeline

Start
2006-06
Primary completion
—
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PRX-08066 Small molecule — —